ADT for Prostate Cancer Tied to Impaired Cognition

This article originally appeared here.
Share this content:
ADT for Prostate Cancer Tied to Impaired Cognition
ADT for Prostate Cancer Tied to Impaired Cognition

WEDNESDAY, May 13, 2015 (HealthDay News) -- Men undergoing androgen-deprivation therapy (ADT) to treat prostate cancer may experience impaired cognitive function within the first six months that persists for at least a year, a new study suggests. The report was published online May 11 in the Journal of Clinical Oncology.

Brian Gonzalez, Ph.D., of the Moffitt Cancer Center in Tampa, Fla., and colleagues evaluated 58 prostate cancer patients before they began ADT and six months and 12 months later. The investigators compared them with 84 men who were treated with prostatectomy and 88 men without prostate cancer.

Impaired cognitive functioning was worse for men receiving ADT. But men with the gene mutation rs1047776 were 14 times more likely to have cognitive issues related to ADT than men without this mutation, Gonzalez told HealthDay.

"Men who are considering hormone therapy for prostate cancer should be aware of the possible mental side effects," Gonzalez said. Gonzalez suspects altering testosterone levels might cause cognitive impairment. But men on ADT also experience fatigue and depression, which might affect their mental abilities, too, he said.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths